• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tidepool Loop automated insulin delivery system wins FDA clearance

February 3, 2023 By Sean Whooley

Tidepool Loop automated insulin delivery software
[Image courtesy of Tidepool]
Tidepool announced recently that the FDA cleared its Tidepool Loop, a “do-it-yourself,” (DIY) automated insulin delivery (AID) system.

Palo Alto, California-based Tidepool is a non-profit diabetes data management group. It created the hybrid, closed-loop AID app for compatibility with multiple insulin pumps and continuous glucose monitors.

The company announced collaborations in the past that include pumps from Insulet and Medtronic. However, it has not yet announced its initial launch device partners. It currently has a development partnership with Dexcom and additional yet-to-be-named medical device companies.

In a blog post on the company’s website last month, Howard Look, Tidepool’s founder, president and CEO, confirmed the FDA clearance.

“What we submitted was different from other [AID] solutions on the market, because our submission did not depend on proprietary insulin pump or continuous glucose monitoring hardware that we develop or control,” Look wrote. “Instead, we submitted Tidepool Loop as a fully interoperable solution for diabetes management. Giving people living with diabetes the freedom and flexibility to collaborate with their healthcare providers, to select the interoperable hardware components, and to establish the settings configurations that work best for their particular situation is part of our bigger goal. FDA clearance is a critical milestone in that roadmap.”

More about Tidepool Loop

Tidepool designed Tidepool Loop for the management of type 1 diabetes in people with diabetes six years of age or older. It has compatibility with the Apple Watch, according to the company’s website.

According to a news release, the algorithm works with compatible integrated CGMs and alternate controller-enabled (ACE) pumps. It automatically increases, decreases and suspends delivery of basal insulin based on CGM readings and predicted glucose values. The algorithm can also recommend and deliver correction boluses when it predicts exceeded predefined thresholds.

The system can now serve as a predicate device for future interoperable AID submissions, Tidepool said. This provides a more clearly defined pathway through the regulatory process. It offers the same opportunity for CGM makers. In addition to defining the regulatory pathway, Tidepool says this creates a path for more rapid diabetes innovation, too.

Grants from JDRF, the Helmsley Charitable Trust and the Tullman foundation helped support the company’s work. Additionally, a diverse community of individual funders impacted by their experience with diabetes supported the development.

“We knew this day would come, but we couldn’t have achieved it without the support of the entire diabetes community, including the FDA,” Look said. “I’d also like to personally acknowledge and celebrate the contributions of the DIY community and participants in the Loop Observational Study conducted by the JAEB Center for Health Research who made this milestone possible.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Technology Tagged With: FDA, tidepool

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS